1	Microhaplotype deep sequencing assays to capture <i>Plasmodium vivax</i> infection lineages	
2		
3	Mariana Kleinecke <sup>1</sup> , Angela Rumaseb <sup>1</sup> , Edwin Sutanto <sup>2</sup> , Hidayat Trimarsanto <sup>1,20</sup> , Kian Soon Hoon <sup>1</sup> , Ashley	
4	Osborne <sup>1</sup> , Paulo Manrique <sup>3,4</sup> , Trent Peters <sup>5</sup> , David Hawkes <sup>5</sup> , Ernest Diez Benavente <sup>6</sup> , Georgia Whitton <sup>7</sup> ,	
5	Sasha V Siegel <sup>7</sup> , Richard D Pearson <sup>7</sup> , Roberto Amato <sup>7</sup> , Anjana Rai <sup>1</sup> , Nguyen Thanh Thuy Nhien <sup>8</sup> , Nguyen	
6	Hoang Chau <sup>8</sup> , Ashenafi Assefa <sup>9</sup> , Tamiru S Degaga <sup>10</sup> , Dagimawie Tadesse Abate <sup>10</sup> , Awab Ghulam Rahim <sup>11</sup> ,	
7	Ayodhia Pitaloka Pasaribu <sup>12</sup> , Inge Sutanto <sup>13</sup> , Mohammad Shafiul Alam <sup>14</sup> , Zuleima Pava <sup>1</sup> , Tatiana Lopera-	
8	Mesa <sup>15</sup> , Diego Echeverry <sup>16</sup> , Tim William <sup>1,17</sup> , Nicholas M Anstey <sup>1</sup> , Matthew J Grigg <sup>1</sup> , Nicholas Day <sup>18,19</sup> ,	
9	Nicholas J. White <sup>18,19</sup> , Dominic P Kwiatkowski <sup>7</sup> *, Rintis Noviyanti <sup>20</sup> , Daniel Neafsey <sup>3,4</sup> , Ric N Price <sup>1,18,19</sup> ,	
10	Sarah Auburn <sup>1,18</sup> **	
11		
12	1.	Menzies School of Health Research and Charles Darwin University, Darwin, Australia
13	2.	Exeins Health Initiative, South Jakarta, Indonesia
14	3.	Harvard T.H. Chan School of Public Health, USA
15	4.	Broad Institute, USA
16	5.	Australian Genome Research Facility, Australia
17	6.	Laboratory of Experimental Cardiology, Department of Cardiology, University Medical Center
18		Utrecht, Utrecht, the Netherlands
19	7.	Wellcome Sanger Institute, Hinxton, UK
20	8.	Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City,
21		Vietnam
22	9.	Ethiopian Public Health Institute, Addis Ababa, Ethiopia
23	10.	College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia
24	11.	Nangarhar Medical Faculty, Nangarhar University, Ministry of Higher Education, Jalalabad,
25		Afghanistan
26	12.	Universitas Sumatera Utara, Medan, Indonesia
27	13.	Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
28	14.	Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh
29		(icddr,b), Dhaka, Bangladesh
30	15.	Universidad de Antioquia, Colombia
31	16.	Departamento de Microbiología, Facultad de Salud, Universidad del Valle, Cali, Colombia
32	17.	Queen Elizabeth Hospital, Malaysia

33 18. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of 34 Oxford, Oxford, United Kingdom 35 19. Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand 36 20. Eijkman Molecular Biology Research Center, National Research and Innovation Agency, 37 Cibinong, Indonesia 38 39 \*Deceased 40 41 \*\*Corresponding author: A/Prof Sarah Auburn, Sarah.Auburn@Menzies.edu.au, Menzies School of 42 Health Research, PO Box 41096, Casuarina, Darwin, NT 0811, Australia; Tel: (+61) 8 8946 8503 43 44 **Key words** 45 Plasmodium vivax; malaria; microhaplotype; relatedness; identity-by-descent; recurrence; relapse; 46 amplicon sequencing 47 48 Abstract 49 50 The elimination of *Plasmodium vivax* is challenged by dormant liver stages (hypnozoites) that can 51 reactivate months after initial infection resulting in relapses that enhance transmission. Relapsing 52 infections confound antimalarial clinical efficacy trials due to the inability to distinguish between 53 recurrences arising from blood-stage treatment failure (recrudescence), reinfection or relapse. Genetic 54 relatedness of paired parasite isolates, measured by identity-by-descent (IBD), can provide important 55 information on whether individuals have had single or multiple mosquito inoculations, thus informing on 56 recurrence origin. We developed a high-throughput amplicon sequencing assay comprising 93 multi-SNP 57 (microhaplotype) P. vivax markers to determine IBD between P. vivax clinical isolates. The assay was 58 evaluated in 659 independent infections from the Asia-Pacific and Horn of Africa, including 108 pairs of 59 infections from a randomized controlled trial (RCT). A bioinformatics pipeline (vivaxGEN-MicroHaps) was 60 established to support data processing. Simulations using *paneljudge* demonstrated low error in 61 pairwise IBD estimation in all countries assessed (all RMSE < 0.12) and IBD-based networks illustrated 62 strong clustering by geography. IBD analysis in the RCT demonstrated a higher frequency of suspected 63 relapses or recrudescence in patients treated with primaguine regimens (0.84) compared to those

without primaquine (0.60). Our results demonstrate the potential to derive information on *P. vivax* IBD
using amplicon sequencing, that informs policy-relevant treatment and transmission dynamics.

66

# 67 Introduction

68

69 Outside of sub-Saharan Africa, *Plasmodium vivax* is becoming the predominant cause of malaria<sup>1</sup>. The 70 control and elimination of *P. vivax* is confounded by the parasite's ability to form dormant liver stages 71 (hypnozoites) that can reactivate weeks to months after initial infection, causing recurrent episodes of 72 malaria known as relapses<sup>2</sup>. The radical cure of vivax malaria requires treatment with both a 73 schizontocidal antimalarial (chloroquine (CQ) or artemisinin combination therapy) combined with a 74 hypnozoiticidal agent (primaquine or tafenoquine)<sup>1</sup>. *P. vivax* resistant to chloroquine (CQR) has been documented in several endemic countries<sup>3,4</sup>, but surveillance of the emergence and spread of CQR is 75 undermined by a lack of reliable molecular markers <sup>2,5</sup>. Although chloroquine efficacy can be defined 76 77 using clinical efficacy trials to determine the risk of recurrent parasitaemia within 28 to 42 days of 78 treatment, estimates are confounded by an inability to distinguish whether recurrent infections are due 79 to schizontocidal treatment failure (recrudescence), reactivation of hypnozoites (relapses), or a new 80 mosquito inoculation (reinfection) <sup>6,7</sup>. In the case a resistant infection is detected, traditional 81 surveillance tools, such as patient travel history, may also be limited in capacity to assess the origin or 82 spread of the given strains within a community  $^2$ . Molecular approaches provide great potential to 83 address these knowledge gaps <sup>6,8</sup>.

84

85 Parasite genotyping of infection pairs (pre- and post-treatment), is well established for interpreting 86 antimalarial clinical efficacy for P. falciparum, to distinguish between recrudescence (same/homologous 87 pairs) and reinfection (different/heterologous pairs)<sup>9</sup>. However, a similar approach to defining clinical 88 efficacy for *P. vivax* infection is undermined by relapses that can be homologous or heterologous to the 89 pre-treatment isolate <sup>10-12</sup>. Genomic studies of *P. vivax* have revealed that a proportion of paired clinical 90 isolates that are classified as heterologous using traditional genotyping methods, can share homology in 91 large segments of the genome, inferring recent common ancestry<sup>13,14</sup>. These familial relationships can 92 be defined using genetic information on identity-by-descent (IBD). Closely related paired infections (e.g., 93 siblings, with  $\geq$ 50% IBD) are more likely to come from a single mosquito inoculation and thus to be 94 relapses rather than reinfections. Genome-wide data are ideal for quantifying IBD. However, this is not 95 feasible in most malaria-endemic settings. Targeted next generation sequencing (NGS)-based methods,

96 such as amplicon sequencing, offer an affordable and versatile alternative <sup>15</sup>. Previously we have 97 established a bioinformatic framework for retrieving genome-wide panels of P. vivax microhaplotype 98 markers; short (200 bp) genomic segments comprising multiple high diversity single nucleotide 99 polymorphisms (SNPs) <sup>8</sup>. Using *in-silico* analyses, we demonstrated that ~100 *P. vivax* microhaplotypes 100 can reliably captured IBD between paired isolates and could be used to define spatio-temporal patterns 101 of *P. vivax* infection<sup>8</sup>. 102 103 In this study, we advanced our previous in-silico work by designing an NGS-based amplicon sequencing 104 assay for 98 P. vivax amplicons, including 93 microhaplotypes that capture IBD accurately in diverse 105 endemic areas. Our rhAmpSeq library preparation protocol incorporates all markers in a single plex 106 reaction and was able to generate high throughput, cost-effective, sensitive and specific data from 107 global isolates. Standard population-level genetic metrics could be applied to the data to highlight 108 potential use cases for National Malaria Control Programs (NMCPs) that will inform P. vivax treatment 109 options and transmission dynamics. 110 111 Results 112 113 A rhAmpSeq multiplex of 93 microhaplotypes with high sensitivity and specificity 114 A two-step multiplex PCR-based library preparation assay was established using rhAmpSeg chemistry 115 (Integrated DNA Technologies, IDT). The multiplex amplifies one species confirmation marker, four 116 putative markers of drug resistance, and 93 microhaplotypes distributed relatively uniformly across the 117 P. vivax genome (Supplementary Data 1; Supplementary Figure 1). To evaluate the assays technical and 118 analytical performance, a total of 750 P. vivax infections were assessed, including 108 paired P. vivax 119 infections from a randomized controlled trial, two P. vivax serial dilution panels, and 10 non-P. vivax 120 control samples (Supplementary Data 2, Supplementary Figure 2). 121 122 The specificity of the assay was evaluated using a selection of 7 non-vivax *Plasmodium* spp. and 3 123 uninfected human DNA controls. None (0/10) of the control samples were permissible to successful read 124 pair calling using DADA2. Examination of amplicon coverage revealed that 58 markers (60% [58/97] after

excluding the mitochondrial species marker) exhibited amplicon coverage <0.9 in all negative controls

126 which would not yield successful read-pairs (Supplementary Figure 3a). Amongst the 39 markers with

127 coverage >0.9 in one or more negative controls, 37 (95%) had read counts <25 in all controls tested, with

only 2 markers (markers 307891 and 313080) exceeding 25 reads and only in the *P. knowlesi* controls
(Supplementary Figure 3b).

130

131 The assay sensitivity was assessed using serial dilutions of two *P. vivax*-infected patient blood samples 132 (KV3 and KV5) under high sample multiplexing (library pooled across 384 samples), using both the 133 standard PCR step 1 DNA input and reaction volumes (referred to as full chemistry with a 20 ul reaction 134 volume) and halving the PCR step 1 DNA input and reaction volumes (referred to as half chemistry with 135 a 10 ul reaction volume). Under full chemistry conditions, depths exceeding 100 reads per marker were 136 observed in the 70 parasite/ul (mean 95-160 across triplicates) and 96 parasite/ul (mean 74-138 across 137 triplicates) sample preparations, as well as in higher densities (Supplementary Figures 4a and c). Under 138 half chemistry conditions, similar depths were observed in the 70 parasite/ul (mean 235-280 across 139 triplicates) and 96 parasite/ul (mean 167-194 across triplicates) sample preparations and higher parasite 140 densities (Supplementary Figures 4b and d).

141

Parasite density defined by microscopic blood film examination may not correlate directly with parasite
DNA yield owing to the presence of multiple life cycle stages in *P. vivax* infections (schizonts, for
example, having greater DNA quantity than ring stages). To address this, we evaluated the threshold
cycle (Ct) values of the KV5 serial dilution using real-time PCR, targeting the *pvmtcox1* gene. Samples
with a Ct <30 (KV5 96 parasite/ul) yielded a mean of ≥100 reads or more, while samples with a Ct <33</li>
(KV5 9.6 parasite/ul) resulted in a mean yield of ≥9 reads (Supplementary Figure 5, Supplementary Table
1).

149

# 150 Geographically diverse application potential

151 A total of 659 *P. vivax* isolates were used to evaluate amplification efficacy from 8 countries across the 152 globe. Successful genotyping was defined as ≥25 reads for >80% of the 97 nuclear genome amplicons 153 and could be achieved in 627 (95.1%) isolates. 500 (79.7%) independent (non-recurrent) samples were 154 taken forward for evaluation of individual marker efficacy and country-specific amplification patterns. A 155 minimum of 5 isolates were available from 6 countries: Afghanistan (n=156), Bangladesh (n=5), 156 Colombia (n=5), Ethiopia (n=213), Indonesia (n=38) and Vietnam (n=83). Aside from 146 samples from 157 East Shewa, Ethiopia, and 38 samples from Sumatra, Indonesia, data from all isolates was generated 158 from a single 384-well run (run 3). One marker (419038) demonstrated poor amplification in all run 3 159 populations with both read (SNP-based) and read-pair (microhaplotype-based) analyses (Supplementary

Data 3, Figure 1). Marker 419038 was therefore excluded from several downstream analyses (see Supplementary Figure 1 for usage). However, increasing the primer concentration for marker 419038 enhanced amplification in later runs, as demonstrated in the East Shewa and Sumatran samples from runs 5 and 6. Three markers (64721, 354590 and 466426) exhibited a large drop in read-pair counts in a moderate proportion of samples after denoising with *DADA2* (Figure 1b). Marker 354590 was most impacted by the *DADA2* denoising and was excluded from all downstream read-pair analyses. The remaining 93 markers exhibited >50% successful genotype calls in majority of populations assessed.

167

# 168 Accuracy in P. vivax variant calling

169 Using a set of 83 isolates with both whole genome sequencing (WGS) and amplicon sequencing data, the 170 accuracy of variant calling (applying the default 10% minor allele threshold) was confirmed at the 425 171 SNPs within the 93 microhaplotypes. Concordance was observed at 98.3% (32,352/32,923) of the 172 genotype calls (Supplementary Table 2, Supplementary Data 4). Homozygous reference versus 173 homozygous alternate allele discordances contributed 0.06% (19/32,923) of all calls. Most discordant 174 calls reflected heterozygous versus homozygous calls (96.7% (552/571)), likely reflecting differences in 175 the limit of detection of minor clones between the datasets. On further exploring the concordance after 176 applying a 1% minor allele threshold to both datasets, a notable difference was more than doubling of 177 heterozygous amplicon sequencing calls that were homozygous in the WGS dataset (from 225 calls with 178 10% threshold to 550 with 1% threshold; Supplementary Table 3); this trend likely reflects a greater limit 179 of detection in the deep sequencing (amplicon) data.

180

# 181 High potential to capture within-host infection complexity

182 Using a set of 83 isolates with both WGS and microhaplotype data, within-host infection complexity was 183 explored using the Fws and effective MOI (eMOI). As illustrated in Figures 2a and b, there was a strong 184 correlation between the genome-wide Fws and the microhaplotype-based eMOI in each geographic 185 region assessed (Spearman's rank correlation, rho=-0.700 p=2.389e-13). However, amongst 59 186 infections with Fws<sub>20.95</sub> (traditionally used as a cut-off to define monoclonal infections), 5 isolates had 187 >95% probability of being polyclonal according to MOIRE analysis of the microhaplotypes (eMOI range 188 1.08-1.93) (Supplementary Data 5). In contrast, none of the infections defined as polyclonal with 189 genomic data (Fws<0.95) were monoclonal with the microhaplotypes (all 100% probability of 190 polyclonality).

192 The eMOI distributions in Figures 2c and d illustrate trends in within-host diversity at the country and

193 provincial level in a larger panel of 498 isolates from 4 populations which had over 30 isolates available:

194 Afghanistan (n=158), Indonesia (n=38), Ethiopia (n=213) and Vietnam (n=89). The data reveals

- 195 differences within-country in Afghanistan, where Laghman exhibited a trend (not significant) of lower
- 196 eMOI than Nangahar (Wilcoxon rank sum test, *p*=0.324). The lowest eMOI distribution was observed in
- 197 Sumatra, Indonesia, suggestive of low endemicity relative to the other sites.
- 198

# 199 *Effective IBD capture*

To assess the ability of the microhaplotype panel to capture IBD accurately, we used *paneljudge* (an R

201 package to judge the performance of a panel of genetic markers using simulated data) to simulate the

202 relative mean square error (RMSE) in estimation of five pairwise IBD states: IBD=0 (unrelated infections),

203 IBD=0.25 (half-siblings), IBD=0.5 (siblings), IBD=0.75 (highly related), and IBD=1 (identical clones). The

simulations were run in the 4 major populations (Afghanistan, Ethiopia, Indonesia and Vietnam) using

205 data from the 92 assayable microhaplotypes, revealing moderately high diversity (mean diversity range

206 0.44-0.65) and low RMSE (<0.12 for all pairwise IBD states) in each population (Supplementary Figure 6,</li>
 207 Figure 3).

208

### 209 **Potential of microhaplotype-based IBD to inform on recurrence**

210 To demonstrate the potential of the assay to inform on the origin of recurrences, the microhaplotype-

211 based IBD was determined using *DCifer* on data from 108 pairs of initial and recurrent infections

212 (Supplementary Data 6). These isolates came from individuals enrolled into a randomized controlled trial

- 213 at two sites in Ethiopia and treated with either chloroquine (CQ), CQ plus primaquine, artemether-
- 214 lumefantrine (AL) or AL plus primaquine<sup>16</sup>. As illustrated in Figure 4a, the patients treated without
- primaquine had a higher frequency of highly related pairs (arbitrary IBD threshold  $\geq 0.25$ ), compared to

those treated with primaquine, consistent with a greater risk of relapsing and recrudescent infections. In

- total, 84% (74/88) of paired isolates in patients not treated with primaquine had IBD ≥25% compared to
- 218 60% (12/20) of those treated with primaquine ( $\chi$ 2 = 4.44, p=0.0351). Overall, 20% (18/70) of paired
- 219 isolates recurring within 120 days of treatment had low relatedness (IBD <25%) compared to 55%
- 220 (11/20) recurring after 120 days; ( $\chi$ 2 = 8.22, *p*=0.004), consistent with a rising proportion of reinfections

at later time points (Figure 4b).

222

# 223 Spatial transmission potential

224 The utility of the marker panel to define spatial transmission dynamics was explored using the isolates 225 from Afghanistan, Ethiopia, Indonesia and Vietnam. As illustrated in the PCoA and neighbour-joining 226 trees in Figures 5a and 5b, SNP-based identity-by-state (IBS) analyses on 280 infections (with <50% 227 probability of polyclonality) demonstrated differentiation between borders. In accordance with the low 228 eMOI distribution, isolates from Sumatra, Indonesia, revealed clusters of genetically identical infections 229 indicative of clonal expansion. IBD analyses on the microhaplotype panel conducted in both clonal and 230 polyclonal infections (n=498) from the same sites revealed evidence of local and inter-site transmission 231 networks and confirmed the clonal clustering in Sumatra (Figures 6a-d).

232

# 233 Effective Plasmodium species confirmation

In addition to the microhaplotypes, a previously described mitochondrial amplicon was included in the
assay to confirm *Plasmodium* spp. <sup>17</sup>. The assay amplifies coordinates PvP01\_MIT\_V2:2904-3149, which
include species-specific SNPs and indels. Using *P. vivax* samples from a range of countries, and *P.
<i>falciparum*, *P. malariae*, *P. ovale* spp. and *P. knowlesi* negative controls, we confirmed amplification of
the mitochondrial marker at moderate to high depth and coverage in all *Plasmodium* species (range 285212) (Supplementary Table 4). Concordance between PCR-based and mitochondrial species
classification was confirmed for each of the *Plasmodium* samples.

241

#### 242 Drug resistance candidates

243 Our assay included a non-exhaustive selection of amplicons encompassing markers of antimalarial drug 244 resistance including the multidrug resistance 1 (pvmdr1) 976 and 1076 loci, and dihydropteroate 245 synthase (pvdhps) 383 and 553 loci that have been associated with ex vivo or clinical phenotypes (see 246 <sup>18</sup>). The dihydrofolate reductase (*pvdhfr*) 57, 58, 61 and 117 loci did not multiplex effectively with the 247 other markers based on bioinformatic predictions and were thus not included. The prevalence of the 248 variants by population is summarized in Figure 7a and Supplementary Table 5. The prevalence of the 249 pvmdr1 Y976F variant, the most widely characterized candidate of CQR, ranged from 0% in Afghanistan 250 to 100% in Sumatra, Indonesia <sup>19</sup>. The F1076L variant, which has also been implicated in CQR, exceeded 251 90% frequency in all 4 countries. The prevalence of A383G mutation in *pvdhps*, a marker of antifolate 252 resistance, varied highly, ranging from 2% in Afghanistan to 80% in Vietnam. No pvdhps A553G 253 mutations were observed in any country.

254

255 We also explored the prevalence of the *pvmdr1* Y976F variant in the Ethiopian RCT cases

256 (Supplementary Data 6, Figure 7b). Amongst 141 day 0 samples with successful microhaplotype and

257 *pvmdr1* 976 genotyping, Y976F prevalence was 52% (73/141). The prevalence of Y976F mutants

amongst recurrences occurring before day 63 in the CQ only arm with IBD >=0.95 relative to the prior

259 infection (likely CQ recrudescence) was not significantly different from the day 0 samples, but sample

- size was small (7/12, 58%, chi-square, *p*=0.892).
- 261

# 262 Discussion

263

We have established a highly multiplexed rhAmpSeq assay (up to 98 amplicons) to address critical
 knowledge gaps in our understanding of antimalarial efficacy and transmission dynamics of *P. vivax*. Our
 assay can be applied to low-density infections and to NGS platforms that are generally available in
 reference laboratories in malaria-endemic settings.

268

269 A critical requirement of the assay was its ability to be implemented in surveillance frameworks in vivax-270 endemic countries. This necessitated high sensitivity to genotype low-density *P. vivax* infections at 271 affordable cost using locally accessible sequencing platforms. With full chemistry, our analyses of serial 272 dilutions demonstrated yields of >100 mean read depth when parasite density was >70 per microliter 273 whole blood. Defining a meaningful assay sensitivity with amplicon sequencing approaches is 274 challenging as several factors other than parasite density can impact on read depth, including the yield 275 of the sequencing platform used, the level of sample multiplexing, the relative target biomass of other 276 samples on the same run, and whether a pre-amplification step is applied. To stress-test our assay, we 277 evaluated the sensitivity of target detection under conditions at the lower end of potential sequence 278 yield at the benefit of lower processing cost. Sensitivity evaluations were undertaken on a MiSeq 279 platform, which is the most widely available platform in malaria endemic settings. The paired end read 280 yield per run is approximately 20-30 million for the MiSeq compared to 260-800 million and up to 40 281 billion on the NextSeq and NovaSeq platforms, opening the possibility for even greater yield if the 282 setting permits. Furthermore, samples could be pooled and did not require pre-amplification with 283 selective Whole Genome Amplification (sWGA) or Primer Extension Preamplification (PEP) <sup>20,21</sup>. Our 284 rationale was that the rhAmpSeq RNase H2 enzyme-dependent amplicon sequencing chemistry should 285 reduce the need for pre-amplification steps relative to standard AmpSeg as it minimizes spurious 286 primer-primer interactions and off-target amplification <sup>22</sup>.

#### 287

288 Another essential data analysis requirement of our assay was the ability to generate genetic data that 289 effectively capture pairwise IBD in *P. vivax* infections with the aim of defining the origin of recurrent 290 infections. Previously described P. vivax amplicon sequencing assays, such as a widely used 42-SNP 291 barcode, have not comprised the density of SNPs needed to capture IBD accurately <sup>8,23,24</sup>. Previously 292 using *in-silico* methods, we demonstrated that panels of ~100 P. vivax microhaplotypes can capture 293 pairwise IBD states ranging from 0 (unrelated) to 1 (clonally identical) with low error (RMSE under 0.12) 294 <sup>8</sup>. In our current study, we applied the same *in-silico* models to demonstrate that, despite less optimal 295 spacing and slightly fewer markers than in the *in-silico* panels, our assayable set of microhaplotypes has 296 comparably low error in IBD estimation at simulated states of 0, 0.25, 0.5, 0.75 and 1 (RMSE under 0.12 297 with 92 microhaplotypes). We also note the adaptability of the rhAmpSeq protocol, enabling addition of 298 new markers, which could be selected to cover genomic regions with low marker density. The software 299 developed in our previous study supports microhaplotype selection that can be customized to specific 300 populations or for specific marker traits <sup>8</sup>.

301

302 In addition to the *in-silico* analysis, we explored microhaplotype-based IBD patterns between pre and 303 post treatment peripheral blood isolates collected from a clinical trial conducted in Ethiopia <sup>16</sup>. Our 304 results demonstrated a higher proportion of highly related but non identical (IBD 0.25-0.95) paired 305 isolates in patients not treated with primaguine, which we postulate reflects a greater risk of relapses in 306 the absence of radical cure. We also observed a higher frequency of clonally identical infection pairs 307 (IBD  $\geq 0.95$ ) in patients not treated with primaguine, likely reflecting a combination of relapses and 308 recrudescence events, that can be further dissected using time-to-event analyses <sup>25</sup>. Lastly, we observed 309 a greater frequency of paired infections with low relatedness (IBD < 0.25) after 4 months consistent with 310 an increasing risk of reinfections during prolonged follow-up after antimalarial treatment. These findings 311 concur with expectations and thus contribute proof of concept on the utility of genetics to inform on 312 recurrence. Data from known relapse events, i.e. from individuals who were relocated to non-endemic 313 areas, will be needed to confirm these findings. Further work is also needed to dissect the potential 314 contribution of the splenic reservoir to recurrent *P. vivax* infections. Lastly, the incorporation of genetic 315 data with time-to-event information using modeling approaches that can handle polyclonal infections, 316 such as the PV3Rs software will greatly inform recurrence classification 317 (https://github.com/aimeertaylor/Pv3Rs). The data have been made open access to support further

318 developments in this space.

#### 319

320 The microhaplotype data produced in this study also provides evidence of the potential for our assay to 321 inform spatial patterns of diversity and connectivity. At a macro-epidemiological level, there was a 322 distinct separation of populations by national boundaries, that could facilitate detection of cross-border 323 importation of infection. Within countries, trends in within-host diversity and connectivity highlighted 324 different transmission dynamics in Sumatra, Indonesia, relative to other sites. Relatively low prevalence 325 of polyclonal infections and large clonal clusters supported low transmission and subsequent inbreeding 326 in Sumatra relative to the other sites. The observed patterns infer that Sumatra is approaching the pre-327 elimination phase and may be receptive to targeted rather than broad scale intervention approaches. 328 Within countries, we also observed evidence of moderate to large local transmission networks, largely 329 confined to specific sites but with some connections across sites. As the data repositories grow, it should 330 be possible to better define the major transmission networks within local regions and their 331 epidemiological context to inform on major reservoirs of infection and routes of infection spread 332 between communities.

333

334 Our panel included a non-exhaustive selection of *P. vivax* drug resistance candidates. The markers and 335 mechanisms of resistance to the more widely used drugs such as chloroquine, artemisinin and partner 336 drugs are not well understood in P. vivax<sup>5</sup>. The inference on treatment failure that can be made on the 337 available markers, including those incorporated in our panel, is therefore limited from an NMCP 338 perspective. However, the adaptability of the rhAmpSeq protocol ensures that new drug resistance 339 markers can be readily added to the panel as they arise. Insights from the current selection of 340 candidates included notable variation between countries in the prevalence of the *pvmdr1* Y976F variant, 341 which has been implicated as a minor modulator of chloroquine (CQ) resistance <sup>19</sup>. The Y976F variant 342 was present at 100% frequency in Sumatra, Indonesia. To our knowledge, this is the first report on 343 Y976F in Sumatra, and aligns with the high prevalence (100%) of this variant in Papua province, Indonesia, a region that has historically harbored high-grade CQ resistant *P. vivax* infections <sup>19,26,27</sup>. 344 345 Although not at fixation, high prevalence of the Y976F variant was also observed in Vietnam (73%) and 346 Ethiopia (41%), but not in Afghanistan (0%). Therapeutic efficacy surveys report low level (<10%) CQ 347 resistance in Ethiopia, Vietnam and Afghanistan, while 16-65% failures by day 28 have been reported in Sumatra, Indonesia <sup>28-36</sup>. The connection between the Y976F variant and clinical CQ efficacy is also 348 349 unclear. Our exploration of the Y976F variant in recurrent cases from the CQ only arm of an RCT 350 conducted in Ethiopia in 2015 revealed a non-significant difference in prevalence (58%) relative to the

baseline study set (51%). However, the sample size was small, with only 12 recurrence pairs in the CQ
arm meeting the IBD and pre-day 63 requirement. Further exploration of phenotypic associations
utilizing IBD and time-to-event data are needed in endemic settings with evidence of higher grade CQ
resistance.

355

356 The panel also includes a previously described mitochondrial amplicon, comprising SNPs and indels that 357 support *Plasmodium* spp. determination <sup>17</sup>. We used the amplicon to successfully confirm *Plasmodium* 358 spp. in a selection of non-P. vivax controls. A caveat of the assay is the inability to distinguish P. ovale 359 curtisi from *P. ovale wallikeri*. However, this could be addressed with the addition of other 360 mitochondrial amplicons <sup>37</sup>. Although most assays displayed high specificity to *P. vivax*, several primers 361 yielded amplicons of *P. knowlesi* DNA with high coverage (>0.9) and moderate to high read depth. 362 Although P. knowlesi is less common in Southeast Asia outside of Malaysian and Indonesian Borneo and 363 considering that *P. vivax* has been eliminated from Malaysia, the *Plasmodium* spp marker may still be 364 helpful to detect potential mixed P. vivax and P. knowlesi infections which could yield inaccurate 365 genotypes at the specified markers.

366

367 Library preparation costs were approximately \$AUD 46 per sample for our study but can be

368 approximately halved (to \$AUD 23) by using half-chemistry reaction volumes for PCR 1. We observed

- 369 similar sensitivity between the full- and half-chemistry reactions in our serial dilution experiments.
- 370

371 In summary, the tools generated in our study provide a major in-road to establishing high-throughput

372 genetic data on *P. vivax* at reasonable cost that can provide policy relevant information on transmission

373 dynamics, parasite reservoirs and the spread of infection across national and provincial borders.

374

# 375 Methods

376

#### 377 Marker selection and assay design

378 193 microhaplotype markers, 5 drug resistance candidates, and two mitochondrial *Plasmodium* species-

- 379 confirmation markers, were selected for assay design (Supplementary Data 1). The set of 193
- 380 microhaplotypes were derived from two 100-microhaplotype panels (referred to as the high-diversity
- 381 and the random microhaplotype panels respectively based on the SNP filtering methods) that we
- 382 previously demonstrated exhibit high accuracy in IBD determination <sup>8</sup>. The rationale for selecting two

383 panels was based on expectation that some markers in the preferred panel (the high-diversity panel) 384 might not be assayable. The drug resistance candidates were not chosen to reflect an exhaustive list of 385 resistance candidates but rather a selection of SNPs that have previously been associated with ex vivo or 386 clinical phenotypes <sup>18</sup>. The species-confirmation markers have been described in a previous malaria 387 amplicon panel <sup>17</sup>. Primers and multiplex pools were designed by Integrated DNA Technologies (IDT). 388 Primer specifications included non-mapping to the human (GRCh38.p14), P. falciparum (Pf3D7), P. 389 malariae (PmUG01), P. ovale wallikeri/curtisi (GH01), and P. knowlesi (PKNH) reference genomes. A 390 variant calling format (VCF) file for the open-access MalariaGEN Pv4.0 dataset, comprising 911,901 high-391 quality variants at 1,895 global *P. vivax* samples, was also provided to confirm non-mapping to highly 392 variable regions of the *P. vivax* genome <sup>38</sup>. A set of 148 markers that met the described primer 393 specifications, and compatible within a single-plex reaction, were taken forward for a pilot experimental 394 run, comprising 176 positive and 16 negative controls (Supplementary Data 1). From the pilot data (not 395 presented here), a set of 98 markers were selected for the final assay (Supplementary Data 1). 396 Requirements for the final panel included high specificity to *P. vivax* and approximate uniform

397 microhaplotype distribution across the genome (Supplementary Figure 1).

#### 398

# 399 Patient samples

400 The sensitivity and specificity of the 98-plex assay was evaluated using *P. vivax*-infected serial blood 401 dilutions and unmodified P. vivax-infected blood samples, stored as dried blood spots or refrigerated 402 whole blood in EDTA-coated microtainer or vacutainer tubes. The dilution series were prepared by 403 mixing each of the three P. vivax-infected whole blood samples (microscopy-determined parasite 404 densities of 740 to 960 parasites/ul blood) with uninfected human whole blood at 10-fold serial dilutions 405 (0.7 to 0.96 parasites/ul blood). Whole blood samples from uninfected human (n=3), P. falciparum (n=2), 406 P. malariae (n=2), P. ovale (n=1), and P. knowlesi (n=3) were included as negative controls. The samples 407 were collected within the framework of previously described clinical trials and cross-sectional surveys, 408 as well as returning travelers presenting with malaria at the Royal Darwin Hospital, Australia, and represented 8 vivax-endemic countries (Supplementary Data 2) <sup>39-42</sup>. DNA extraction was undertaken 409 410 using Qiagen's QIAamp kits for respective dried blood spots or whole blood.

411

#### 412 Real-time PCR

413 The cycle threshold (Ct) values of *P. vivax* DNA samples were assessed using an Applied Biosystems®

414 QuantStudio<sup>™</sup> 6 Flex Real-Time PCR System (ThermoFisher Scientific) with a TaqMan real-time PCR-

based assay, as adapted from <sup>43</sup>. This assay detects *P. vivax* by targeting a conserved region of the
mitochondrial cytochrome oxidase 1 gene (*pvmtcox1*) <sup>43</sup>. Each qPCR reaction mixture consisted of 10 ul
TaqMan Universal Mix II master mix (ThermoFisher Scientific), 1.6 ul of both the forward and reverse *Pv- mtcox1* primers (10 uM), 0.8 µL of the *pvmtcox1* probe (10 uM), 2 ul H2O, and 4 ul gDNA. The
thermocycling conditions included an initial denaturation at 95°C for 10 min, followed by 45 cycles of
denaturation at 95°C for 15 sec, and annealing and elongation at 60°C for 1 min. Data analysis was
performed using QuantStudio RT-PCR software to derive the threshold cycle (Ct) values.

422

# 423 Whole genome sequencing (WGS) data

424 A combination of newly generated and pre-existing WGS data was used in the study (Supplementary 425 Data 7). The pre-existing WGS data were derived from the MalariaGEN Pv4.0 repository <sup>38</sup>. Briefly, the 426 data were generated using 100-150 bp paired-end sequencing on a HiSeg or MiSeg instrument 427 (Illumina). The resultant reads were analyzed with the biallelic SNP pipeline used in this study, which 428 incorporated read mapping against the P. vivax P01 reference using BWA-MEM2 and variant calling 429 using the Genome Analysis Toolkit v4.5<sup>44,45</sup>. A total of 911,901 high-quality biallelic SNP loci were 430 derived. Positions with less than 5 reads were considered genotype failures, with a minimum of two 431 reference and two alternate alleles, and a minimum of 10% of minor allele read frequency required to 432 define a genotype as heterozygous. The new WGS data were generated using microscopy-positive P. 433 vivax infections collected within a therapeutic efficacy survey of chloroquine, conducted in Arbaminch, 434 Ethiopia in 2019. Briefly, DNA was extracted from 1-2 ml white blood cell-depleted (Plasmodipur-435 filtered) whole blood samples using Qiagen's QIAamp blood midi kits. Library preparation and 436 sequencing was conducted on the gDNA at the Wellcome Sanger Institute using the Illumina HiSeq 437 platform, generating 150bp paired reads. The resultant reads were mapped against the PvP01 reference 438 genome and genotype calling was conducted using the 911,901 MalariaGEN Pv4.0 SNPs, following the 439 same methods. Only samples with more than 50% genotype calls were included in the analysis.

440

#### 441 rhAmpSeq library preparation and sequencing

Library preparation of the 98-plex marker panel was conducted using IDT's rhAmpSeq methodology.
Details on the protocol are provided in Supplementary Note 1 and on the protocols.io website
(<u>https://www.protocols.io/file/rfffce597.pdf</u>). In brief, genomic DNA samples were subject to a single
multiplexed (all 98 targets amplified within one pool) primer amplification using pre-balanced,
customized, rhAmpSeq primers. The product was diluted and subject to a second PCR, incorporating

- 447 indexes and Illumina sequencing adaptors. The products from the second PCR step were pooled
- 448 (incorporating up to 384 samples), resulting in the final library. The library was bead purified, assessed
- 449 for quality (fragment size and quantity), and sequenced with 150 bp paired-end clusters on a MiSeq
- 450 instrument (Illumina).
- 451

#### 452 Amplicon data read mapping and variant calling

- 453 Options for variant calling from fastq files at both biallelic SNPs and multiallelic microhaplotypes were
- 454 incorporated into the data processing pipeline, which is available at
- 455 <u>https://github.com/vivaxgen/MicroHaps</u> and described in Supplementary Note 2. In short, for the
- 456 biallelic SNP pipeline, vcfs are generated using a pipeline that conducts read mapping via *bwa-mem2*,
- 457 and variant calling with GATK v4.5. Positions with less than 25 reads were considered genotype failures,
- 458 with a minimum of two reference and two alternate alleles, and a minimum of 10% of minor allele read
- 459 frequency required to define a genotype as heterozygous. For the microhaplotype-calling pipeline, we
- 460 adapted an existing *P. falciparum* microhaplotype pipeline which utilizes the *DADA2* software for
- 461 denoising <sup>46</sup>. The microhaplotype pipeline includes adapter and primer removal with *cutadapt*, and
- 462 custom scripts to postprocess *DADA2* output.
- 463

# 464 *Population genetic measures*

- 465 For the resulting microhaplotype data, within-host infection diversity was characterized by the effective
- 466 multiplicity of infection (eMOI) metric using *MOIRE* software <sup>47</sup>. For the WGS data, within-host diversity
- 467 was characterized using the  $F_{WS}$  score, calculated from biallelic SNP loci <sup>48</sup>. The R-based *paneljudge*
- 468 package was used to assess the relative mean square error (RMSE) of the microhaplotype markers at
- 469 IBD levels of 0 (unrelated), 0.25 (half-siblings), 0.5 (siblings), 0.75 and 1.0 (identical)
- 470 (<u>https://github.com/aimeertaylor/paneljudge</u>). Between-sample IBD was measured using *DCifer*<sup>49</sup>.
- 471 Network plots were generated using the *R*-based *igraph* package (<u>https://github.com/igraph</u>). Identity-
- 472 by-state (IBS)-based measures of genetic distance were calculated using the *R*-based ape package,
- 473 treating the microhaplotypes as multiallelic variants, and presented as neighbour-joining trees and
- 474 principal coordinate (PCoA) plots <sup>50</sup>.
- 475

#### 476 Plasmodium speciation based on genetic distance matrix

- 477 To confirm the *Plasmodium* spp., amplicons targeting a universal mitochondrial sequence region were
- 478 mapped to a synthetic genome. The synthetic genome was constructed using reference genomes of five

479 Plasmodium species: PvP01 MIT v2:2904-3149 (P. vivax), PmUG01 MIT v1:1115-1361 (P. malariae),

480 PKNH\_MIT\_v2:1632-1875 (*P. knowlesi*), Pf3D7\_MIT\_v3:1634-1877 (*P. falciparum*), and

481 PocGH01\_MIT\_v2:2894-3137 (*P. ovale*). The synthetic genome was generated through an alignment

482 containing the specified regions within the reference genomes; aligned using muscle <sup>51</sup>.

483 For each sample with more than 10 reads and >0.9 coverage in the mitochondrial sequence region, the

484 reads were mapped to the synthetic genome. The mapped reads were used to call a consensus

485 sequence using iVar <sup>52</sup>. The consensus sequence was then compared pairwise to each sequence within

- 486 the multi-sequence alignment, containing all the reference genomes. The species of the sample was
- 487 determined based on the highest pairwise alignment score.
- 488

#### 489 Inclusion and ethics

490 The authors in this study combine researchers from the malaria-endemic countries represented in the 491 study (Afghanistan, Bangladesh, Colombia, Ethiopia, Indonesia and Vietnam) and nonmalaria endemic 492 areas. The researchers from malaria-endemic countries were involved throughout the research process 493 to ensure that the assays are implementable and impactful in local communities affected by malaria. All 494 samples in this study were derived from blood samples obtained from patients positive for malaria and 495 collected with informed consent from the patient, or patient parent / legal guardian where individuals 496 were less than 18 years of age. At each location, sample collection was approved by the appropriate 497 local institutional ethics committees. The following committees gave ethical approval for the partner 498 studies: Human Research Ethics Committee of NT Department of Health and Families and Menzies 499 School of Health Research, Darwin, Australia; Islamic Republic of Afghanistan Ministry of Public Health 500 Institutional Review Board, Afghanistan; ICDDR, B Ethical Review Committee, Bhutan; Research Ethics 501 Board of Health, at the Ministry of Health in Bhutan; Comite Institucional de Etica de Investigaciones en 502 Humanos, Colombia; Comite de Bioetica Instituto de Investigaciones Medicas Facultad de Medicina 503 Universidad de Antioquia, Colombia; Armauer Hansen Research Institute Institutional Review Board, 504 Ethiopia; Addis Ababa University College of Natural Sciences, Ethiopia; Addis Ababa University, Aklilu 505 Lemma Institute of Pathobiology Institutional Review Board, Ethiopia; National Research Ethics Review 506 Committee of Ethiopia; Eijkman Institute Research Ethics Committee, Jakarta, Indonesia; Research 507 Review Committee of the Institute for Medical Research and the Medical Research Ethics Committee 508 (MREC), Ministry of Health, Malaysia; Scientific and Ethical Committee of the Hospital for Tropical 509 Diseases in Ho Chi Minh City, Vietnam; The Ministry of Health Evaluation Committee on Ethics in 510 Biomedical Research, Vietnam.

### 511

# 512 Data availability

- 513 The MalariaGEN Pv4.0 WGS data are available through the European Nucleotide Archive <sup>38</sup>. The WGS
- reads from the newly generated, high-quality, Ethiopian *P. vivax* infections are available through the
- 515 European Nucleotide Archive. The ENA accession numbers for all WGS samples used here are listed in
- 516 Supplementary Data 7. All high-quality (pass) microhaplotype-based parasite reads will be made
- 517 available in the European Nucleotide Archive at publication (Supplementary Data 2).
- 518

# 519 *Code availability*

- 520 The pipelines for retrieving SNP data in variant call format (vcf), as well as microhaplotype data in
- 521 Compact Idiosyncratic Gapped Alignment Report (cigar) string format, are available on GitHub at
- 522 <u>https://github.com/vivaxgen/MicroHaps</u>.
- 523

# 524 <u>References</u>

- 525
- WHO. World Malaria Report 2022. World Health Organization; Geneva 2022. (2022).
   Auburn, S., Cheng, Q., Marfurt, J. & Price, R. N. The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools. *PLoS medicine* 18, e1003560,
- 529 doi:10.1371/journal.pmed.1003560 (2021).
- 530 3 Price, R. N. *et al.* Global extent of chloroquine-resistant Plasmodium vivax: a systematic review
  531 and meta-analysis. *The Lancet. Infectious diseases* 14, 982-991, doi:10.1016/S1473532 3099(14)70855-2 (2014).
- Commons, R. J. *et al.* The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical
  trials. *International journal for parasitology. Drugs and drug resistance* 7, 181-190,
  doi:10.1016/j.ijpddr.2017.03.003 (2017).
- 5365Buyon, L. E., Elsworth, B. & Duraisingh, M. T. The molecular basis of antimalarial drug resistance537in Plasmodium vivax. International journal for parasitology. Drugs and drug resistance 16, 23-37,538doi:10.1016/j.ijpddr.2021.04.002 (2021).
- 539 6 Popovici, J. *et al.* Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess
  540 Chloroquine Efficacy for Plasmodium vivax Malaria. *The Journal of infectious diseases* 219, 315541 322, doi:10.1093/infdis/jiy484 (2019).
- 5427White, N. J. & Imwong, M. Relapse. Advances in parasitology **80**, 113-150, doi:10.1016/B978-0-54312-397900-1.00002-5 (2012).
- 5448Siegel, S. V. *et al.* Lineage-informative microhaplotypes for recurrence classification and spatio-545temporal surveillance of Plasmodium vivax malaria parasites. *Nature communications* **15**, 6757,546doi:10.1038/s41467-024-51015-3 (2024).
- 5479Snounou, G. & Beck, H. P. The use of PCR genotyping in the assessment of recrudescence or548reinfection after antimalarial drug treatment. *Parasitol Today* 14, 462-467, doi:10.1016/s0169-5494758(98)01340-4 (1998).

550 10 Imwong, M. et al. Relapses of Plasmodium vivax infection usually result from activation of 551 heterologous hypnozoites. The Journal of infectious diseases 195, 927-933, doi:10.1086/512241 552 (2007).553 11 Chen, N., Auliff, A., Rieckmann, K., Gatton, M. & Cheng, Q. Relapses of Plasmodium vivax 554 infection result from clonal hypnozoites activated at predetermined intervals. The Journal of 555 infectious diseases 195, 934-941, doi:10.1086/512242 (2007). 556 Abdullah, N. R. et al. Plasmodium vivax population structure and transmission dynamics in 12 557 Sabah Malaysia. PloS one 8, e82553, doi:10.1371/journal.pone.0082553 (2013). 558 13 Bright, A. T. et al. A high resolution case study of a patient with recurrent Plasmodium vivax 559 infections shows that relapses were caused by meiotic siblings. PLoS neglected tropical diseases 560 8, e2882, doi:10.1371/journal.pntd.0002882 (2014). 561 Popovici, J. et al. Genomic Analyses Reveal the Common Occurrence and Complexity of 14 562 Plasmodium vivax Relapses in Cambodia. *mBio* 9, doi:10.1128/mBio.01888-17 (2018). 563 15 Ruybal-Pesantez, S. et al. Molecular markers for malaria genetic epidemiology: progress and 564 pitfalls. Trends in parasitology 40, 147-163, doi:10.1016/j.pt.2023.11.006 (2024). 565 Abreha, T. et al. Comparison of artemether-lumefantrine and chloroquine with and without 16 566 primaguine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized 567 controlled trial. PLoS medicine 14, e1002299, doi:10.1371/journal.pmed.1002299 (2017). 568 17 Jacob, C. G. et al. Genetic surveillance in the Greater Mekong subregion and South Asia to 569 support malaria control and elimination. eLife 10, doi:10.7554/eLife.62997 (2021). 570 18 Price, R. N., Auburn, S., Marfurt, J. & Cheng, Q. Phenotypic and genotypic characterisation of 571 drug-resistant Plasmodium vivax. Trends in parasitology 28, 522-529, 572 doi:10.1016/j.pt.2012.08.005 (2012). 573 19 Suwanarusk, R. et al. Chloroguine resistant Plasmodium vivax: in vitro characterisation and 574 association with molecular polymorphisms. PloS one 2, e1089, 575 doi:10.1371/journal.pone.0001089 (2007). 576 20 Cowell, A. N. et al. Selective Whole-Genome Amplification Is a Robust Method That Enables 577 Scalable Whole-Genome Sequencing of Plasmodium vivax from Unprocessed Clinical Samples. 578 *mBio* 8, doi:10.1128/mBio.02257-16 (2017). 579 21 Arneson, N., Hughes, S., Houlston, R. & Done, S. Whole-Genome Amplification by Improved 580 Primer Extension Preamplification PCR (I-PEP-PCR). CSH Protoc 2008, pdb prot4921, 581 doi:10.1101/pdb.prot4921 (2008). 582 22 Dobosy, J. R. et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide 583 polymorphism detection using blocked cleavable primers. BMC Biotechnol 11, 80, 584 doi:10.1186/1472-6750-11-80 (2011). 585 23 Baniecki, M. L. et al. Development of a single nucleotide polymorphism barcode to genotype 586 Plasmodium vivax infections. *PLoS neglected tropical diseases* **9**, e0003539, 587 doi:10.1371/journal.pntd.0003539 (2015). 588 Taylor, A. R., Jacob, P. E., Neafsey, D. E. & Buckee, C. O. Estimating Relatedness Between Malaria 24 589 Parasites. Genetics 212, 1337-1351, doi:10.1534/genetics.119.302120 (2019). 590 25 Taylor, A. R. et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. 591 Nature communications 10, 5595, doi:10.1038/s41467-019-13412-x (2019). 592 26 Ratcliff, A. et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. 593 vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Transactions 594 of the Royal Society of Tropical Medicine and Hygiene **101**, 351-359, 595 doi:10.1016/j.trstmh.2006.06.008 (2007). 596 27 Pearson, R. D. et al. Genomic analysis of local variation and recent evolution in Plasmodium 597 vivax. Nature genetics 48, 959-964, doi:10.1038/ng.3599 (2016).

598 28 Assefa, M., Eshetu, T. & Biruksew, A. Therapeutic efficacy of chloroquine for the treatment of 599 Plasmodium vivax malaria among outpatients at Hossana Health Care Centre, southern Ethiopia. 600 Malaria journal 14, 458, doi:10.1186/s12936-015-0983-x (2015). 601 29 Getachew, S. et al. Chloroquine efficacy for Plasmodium vivax malaria treatment in southern 602 Ethiopia. *Malaria journal* **14**, 525, doi:10.1186/s12936-015-1041-4 (2015). 603 30 Thuan, P. D. et al. A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-604 Piperaguine for the Treatment of Plasmodium vivax Infection in Vietnam. The American journal 605 of tropical medicine and hygiene **94**, 879-885, doi:10.4269/ajtmh.15-0740 (2016). 606 31 Phong, N. C. et al. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax 607 to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Malaria 608 journal 18, 10, doi:10.1186/s12936-019-2640-2 (2019). 609 32 Kolaczinski, K., Durrani, N., Rahim, S. & Rowland, M. Sulfadoxine-pyrimethamine plus artesunate 610 compared with chloroquine for the treatment of vivax malaria in areas co-endemic for 611 Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. 612 Transactions of the Royal Society of Tropical Medicine and Hygiene **101**, 1081-1087, 613 doi:10.1016/j.trstmh.2007.06.015 (2007). 614 33 Leslie, T. et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the 615 treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled 616 trial. JAMA 297, 2201-2209, doi:10.1001/jama.297.20.2201 (2007). 617 34 Awab, G. R. et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in 618 Afghanistan: an open randomized, non-inferiority, trial. Malaria journal 9, 105, 619 doi:10.1186/1475-2875-9-105 (2010). 620 35 Sutanto, I. et al. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern 621 Sumatra, western Indonesia. Malaria journal 9, 52, doi:10.1186/1475-2875-9-52 (2010). 622 36 Fryauff, D. J. et al. The drug sensitivity and transmission dynamics of human malaria on Nias 623 Island, North Sumatra, Indonesia. Ann Trop Med Parasitol 96, 447-462, 624 doi:10.1179/000349802125001249 (2002). 625 37 Higgins, M. et al. New reference genomes to distinguish the sympatric malaria parasites, 626 Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Scientific reports 14, 3843, 627 doi:10.1038/s41598-024-54382-5 (2024). 628 MalariaGen et al. An open dataset of Plasmodium vivax genome variation in 1,895 worldwide 38 629 samples. Wellcome open research 7, 136, doi:10.12688/wellcomeopenres.17795.1 (2022). 630 Abreha, T. et al. Correction: Comparison of artemether-lumefantrine and chloroquine with and 39 631 without primaguine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized 632 controlled trial. PLoS medicine 15, e1002677, doi:10.1371/journal.pmed.1002677 (2018). 633 40 Taylor, W. R. J. et al. Short-course primaguine for the radical cure of Plasmodium vivax malaria: 634 a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet 394, 929-938, 635 doi:10.1016/S0140-6736(19)31285-1 (2019). 636 41 Grigg, M. J. et al. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated 637 Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled 638 trial. The Lancet. Infectious diseases 16, 180-188, doi:10.1016/S1473-3099(15)00415-6 (2016). 639 42 Ley, B. et al. G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in 640 Bangladesh: A Prospective Observational Study. PloS one 11, e0154015, 641 doi:10.1371/journal.pone.0154015 (2016). 642 43 Gruenberg, M. et al. Plasmodium vivax molecular diagnostics in community surveys: pitfalls and 643 solutions. Malaria journal 17, 55, doi:10.1186/s12936-018-2201-0 (2018).

644 44 Auburn, S. et al. A new Plasmodium vivax reference sequence with improved assembly of the 645 subtelomeres reveals an abundance of pir genes. Wellcome open research 1, 4, 646 doi:10.12688/wellcomeopenres.9876.1 (2016). 647 45 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. 648 Bioinformatics 25, 1754-1760, doi:10.1093/bioinformatics/btp324 (2009). 649 46 LaVerriere, E. et al. Design and implementation of multiplexed amplicon sequencing panels to 650 serve genomic epidemiology of infectious disease: A malaria case study. Mol Ecol Resour 22, 651 2285-2303, doi:10.1111/1755-0998.13622 (2022). 652 47 Murphy, M. & Greenhouse, B. MOIRE: A software package for the estimation of allele 653 frequencies and effective multiplicity of infection from polyallelic data. *bioRxiv*, 654 doi:10.1101/2023.10.03.560769 (2024). 655 Auburn, S. et al. Characterization of within-host Plasmodium falciparum diversity using next-48 656 generation sequence data. *PloS one* 7, e32891, doi:10.1371/journal.pone.0032891 (2012). 657 49 Gerlovina, I., Gerlovin, B., Rodriguez-Barraquer, I. & Greenhouse, B. Dcifer: an IBD-based 658 method to calculate genetic distance between polyclonal infections. Genetics 222, 659 doi:10.1093/genetics/iyac126 (2022). 660 50 Paradis, E., Claude, J. & Strimmer, K. APE: Analyses of Phylogenetics and Evolution in R language. 661 Bioinformatics 20, 289-290 (2004). 662 Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. 51 663 Nucleic acids research 32, 1792-1797, doi:10.1093/nar/gkh340 (2004). 664 52 Grubaugh, N. D. et al. An amplicon-based sequencing framework for accurately measuring 665 intrahost virus diversity using PrimalSeg and iVar. Genome biology 20, 8, doi:10.1186/s13059-666 018-1618-7 (2019). 667

# 668 Acknowledgements

669 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation INV-043618

- 670 (supporting S.A., D.N and R.N.P). Under the grant conditions of the Foundation, a Creative Commons
- 671 Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version
- that might arise from this submission. The study was also supported by the National Health and Medical
- 673 Research Council of Australia (APP2001083 supporting S.A. and S.V.S.). The whole genome sequencing
- 674 component of the study was supported by the Medical Research Council and UK Department for
- 675 International Development (award number M006212 to D.K.) and the Wellcome Trust (award numbers
- 676 206194 and 204911 to D.K.). The OPRA clinical trial was supported by the Bill & Melinda
- 677 Gates Foundation (OPP1054404 awarded to R.N.P.). We thank the patients who contributed their
- 678 samples to the study, and the health workers and field teams who assisted with the sample collections.
- 679 Whole genome sequencing was undertaken by the Wellcome Sanger Institute, and amplicon sequencing
- 680 was undertaken at the Australian Genome Research Facility (AGRF) and Menzies School of Health
- 681 Research. We thank the staff of the Wellcome Sanger Institute and AGRF for contributions to samples
- 682 logistics, sequencing and informatics. We thank Ruchit Panjal for his assistance with the pipeline set up.

#### 684 Author contributions

- 685 S.A., D. N. and R.N.P. conceived the study. S.A., M.K., A Rumaseb, E.S., and H.T. designed the study. A.
- 686 Rumaseb, T.P., D.H., G.W., S.V.S, N.T.T.N. and S.A. contributed to the laboratory assay design. A
- 687 Rumaseb, T.P., D.H., A.O. and A Rai contributed to genotyping data generation. S.V.S, R.P., R.A. and
- 688 D.P.K. contributed whole genome sequencing data production and informatic support. M.K., H.T., A.O.,
- 689 P.M. and D.N. contributed to bioinformatic pipeline development. M.K., E.S., H.T., K.S.H. and S.A.
- 690 conducted data analysis. E.D.B., N.T.T.N, N.H.C., A.A., T.S.D., D.T.A., A.G.R., A.P.P., I.S., M.S.A., Z.P., T.L.,
- 691 D.E., T.W., N.A., M.G., N.D., N.J.W., D.P.K. and R.N. contributed essential field-based malaria collections
- and metadata, and guidance on the study design and interpretation.
- 693

### 694 Competing Interests

695 The authors declare no competing interests



# 696 <u>Figures</u>

699 Figure 1. P. vivax proportion of samples with more than 25 reads or more than 10 read pairs by country. Heat maps illustrate the proportion of 700 samples with more than 25 reads (panel a) and proportion of samples with more than 10 read pairs derived from DADA2 (panel b) for each 701 marker by country. Markers (x-axis) were ordered by chromosome and coordinate. All samples with genotype failures (<25 reads or <10 read 702 pairs) are presented in black. Microhaplotype markers 64721, 354590, 419038 and 466426 displayed consistently low read-pair counts. 703 Microhaplotype marker 354590 exhibits high individual read counts (panel a) but low read-pair counts (panel b) in all countries and was 704 excluded from all downstream read pair analyses. Data are presented on a total of 500 independent (not including replicates) infections that 705 passed genotyping. The data from Ethiopia are split into dried blood spot (DBS) from a clinical trial conducted in East Shewa Zone and whole 706 blood (WB) extracts from a therapeutic efficacy survey conducted in Gamo Zone for comparative assessment. The DBS versus WB comparisons 707 reveal similar read and read pair counts at all loci.



708

709

710 Figure 2. Microhaplotype-based within-host diversity trends. Panels a) and b) illustrate the level of 711 concordance between genomic (as measured by the Fws) and microhaplotype (as measured by eMOI) 712 data in estimation of within-host *P. vivax* diversity. The boxplots present the median, interguartile range 713 and min and max value. Data are derived from 83 independent P. vivax cases. Overall, high concordance 714 is observed between the two datasets. However, a few infections, including VN0001-321 and 715 VN001 030 circled in panel 4a) display notably higher within-host diversity with microhaplotype versus 716 whole genome sequence data. Panels c) and d) present the eMOI distributions at the country level (c) 717 and provincial level (d), illustrating variation between sites, likely reflecting local endemicity levels. The 718 data in panels c) and d) are based on 498 independent cases.



721 Figure 3. Simulations of IBD estimation in different geographic areas using the microhaplotype panel. 722 Root mean square error (RMSE) of relatedness estimates based on data simulated using five different 723 data-generating relatedness estimates, r (specifically IBD of 0 [unrelated], 0.25 [half-sibling], 0.5 724 [sibling], 0.75 [highly related], and 1 [clonally identical]) with switch rate parameter k set to 5. Data were 725 generated using *paneljudge* software on 91 high performance microhaplotypes and 4 drug resistance 726 markers in independent infections from Afghanistan (n=158), Ethiopia (n=213), Indonesia (n=38) and 727 Vietnam (n=89). In all populations, half-siblings and siblings had the highest RMSE, but this remained 728 below 0.12 in all cases. 729





731 Figure 4. IBD distributions by treatment and time to recurrence in a randomized controlled trial 732 conducted in Ethiopia. Panel a) presents the IBD distributions in initial and recurrent infection pairs 733 across all pairs and grouped by treatment arm; AL (Artemether-Lumefantrine), CQ (Chloroquine), AL+PQ 734 (AL + Primaguine) and CQ+PQ. Panel b) presents the same IBD data grouped by recurrences occurring 735 less versus more than 120 days after the initial infection. Each boxplot presents the median, 736 interguartile range and min and max value. Data are presented on recurrence pairs from 108 737 independent patients, with only one infection pair presented per patient to avoid potential bias (n=108 738 patients, 216 samples). Majority (86%, 93/108) of pairs reflect day 0 and recurrence 1 time points. 739 Where the day 0 or recurrence 1 infections failed genotyping or had inconclusive clinical metadata, 740 consecutive pairs of recurrence 2 to 4 pairs were used instead as the patients received the same 741 treatment up to recurrence 4.

742





744

Figure 5. Identity-by-state-based spatial patterns. Panels a) and b) present Principal Coordinate (PCoA)
plots derived from distance matrices on the microhaplotype calls. High separation of countries is
observed with principal coordinates 1 and 2, with even further separation of Indonesia from Vietnam on
principal coordinate 3. Panels c) and d) present unrooted and rooted, respectively, neighbour-joining
trees based on the same distance matrix as per the PCoA plots. The neighbour-joining trees further
illustrate distinct clustering by country and, additionally, highlight a clonally identical cluster of

- 751 infections in Sumatra, Indonesia. All plots were generated using data on 280 independent, monoclonal
- 752 infections.
- 753







- 759 Sumatra, Indonesia (d). Each shape reflects an infection, colour-coded by site, and with shapes reflecting
- 760 monoclonal (circle) versus polyclonal (square) infections. For each country, connectivity (illustrated by
- 761 connecting lines between shapes) is presented at IBD thresholds of minimum ~25%, 50% and 95% (left
- to right). IBD measures were calculated on the microhaplotype calls using *DCifer* software. At the ~25%
- 763 IBD threshold, large networks (10 or more connected infections) are observed amongst infections from
- the same site, with some connectivity between networks from different sites; these networks shrink
- 765 with increasing IBD in all sites except for Sumatra, Indonesia, where the networks appear to reflect
- 766 clonal clusters (retained at IBD  $\geq$ 95%). All plots were generated using data on independent infections:
- Afghanistan (n=158), Ethiopia (n=213), Vietnam (n=89) and Indonesia (n=38).





769 Figure 7. Amino acid frequencies at P. vivax drug resistance candidates. Panel a) presents proportions 770 and corresponding 95% confidence intervals (CIs) for the given amino acid changes in baseline 771 population samples from each country. All frequencies reflect the suspected drug-resistance-conferring 772 amino acid. All plots were generated using independent samples (n=498). Panel b) presents the 773 proportions of the *pvmdr1* Y976F variant, which has been associated with CQ resistance, in the 774 respective patient groups within the Ethiopian randomized control trial; all genotyped baseline (day 0) 775 infections irrespective of treatment arm (day\_0\_all), all recurrent infections irrespective of treatment 776 arm (recur\_all), all recurrent infections in the CQ only arm (recur\_CQ), all recurrent infections in the CQ

- only arm with IBD>0.95 relative to the prior infection (enhancing probability of recrudescence based on
- genetics; recur\_CQ\_IBD\_095), and all recurrent infections in the CQ only arm occurring prior to day 63
- and with IBD>0.95 relative to the prior infection (enhancing probability of recrudescence based on
- 780 genetic and time-to-event metadata, recur\_CQ\_IBD\_095\_Day63). Sample sizes are annotated in white
- font over the respective bars. ns = non-significant difference in proportion between the indicated
- 782 groups.